ArticleEuropean journal of nuclear medicine and molecular imaging2026
Molecular imaging of fibroblast activation in systemic sclerosis using [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeted depletion of activated fibroblasts via [Frontiers in immunology · 2026Article
- Expanding horizons: radiolabeled FAPI in imaging of autoimmune diseases.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeThis prospective cohort study evaluated the utility of [¹⁸F]AlF-NOTA-FAPI-04 PET/CT for whole-body assessment of fibroblast activation in systemic sclerosis (SSc), correlating organ-specific uptake with clinical indicators of severity and multi-organ dysfunction.
methods31 patients with SSc and 21 patients from a non-SSc cohort underwent total-body [¹⁸F]AlF-NOTA-FAPI-04 PET/CT imaging. Quantitative uptake parameters were measured in lungs, heart, kidneys, skeletal muscles, esophagus, and skin. Clinical assessments were completed within ± 14 days. Inter-organ metabolic correlations were analyzed.
resultsAbnormally elevated FAPI uptake was prevalent in the lungs (96.8%), heart (35.5%), kidneys, and skeletal muscles (12.9%). Compared with the non-SSc cohort, patients with SSc exhibited significantly elevated whole lung SUV
conclusion[¹⁸F]AlF-NOTA-FAPI-04 PET/CT provides a noninvasive, integrative imaging platform for mapping fibroblast activation across multiple organs in SSc. It demonstrated potential for detection of fibrotic burden and inter-organ metabolic profiling. Its sensitivity in gastrointestinal and cutaneous involvement remains limited, warranting further optimization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.